Macrophage migration inhibitory factor in prostatic adenocarcinoma: Correlation with tumor grading and combination endocrine treatment-related changes

Prostate

Volumn 45, Issue 1, 2000, Pages 51-57

  del Vecchio, Maria Teresa ^a   Tripodi, Sergio Antonio ^a   Arcuri, Felice ^a   Pergola, Loreta ^a   Hako, Lizart ^a   Vatti, Rosella ^a   Cintorino, Marcella ^a  

^a UNIVERSITY OF SIENA   (Italy)

Author keywords

Combined endocrine treatment; Gleason scoring system; Immunohistochemistry; MIF; Prostate adenocarcinoma

Indexed keywords

FLUTAMIDE; GONADORELIN AGONIST; MACROPHAGE MIGRATION INHIBITION FACTOR;

ADULT; AGED; ARTICLE; CANCER GRADING; CANCER HORMONE THERAPY; CANCER STAGING; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; ITALY; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROSTATE ADENOCARCINOMA; PROTEIN EXPRESSION;

ADENOCARCINOMA; AGED; ANDROGEN ANTAGONISTS; ANDROGENS; ANTINEOPLASTIC AGENTS, HORMONAL; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BIOPSY, NEEDLE; CELL DIFFERENTIATION; FLUTAMIDE; GONADOTROPIN-RELEASING HORMONE; HUMANS; IMMUNOHISTOCHEMISTRY; MACROPHAGE MIGRATION-INHIBITORY FACTORS; MALE; MIDDLE AGED; NEOADJUVANT THERAPY; PROGNOSIS; PROSTATE; PROSTATIC INTRAEPITHELIAL NEOPLASIA; PROSTATIC NEOPLASMS;

EID: 0033839679     PISSN: 02704137     EISSN: None     Source Type: Journal    
DOI: 10.1002/1097-0045(20000915)45:1<51::AID-PROS6>3.0.CO;2-9     Document Type: Article

References (41)

1. Delayed hypersensitivity in vitro: Its mediation by cell-free substances formed by lymphoid cell antigen interaction
2. Mechanism of a reaction in vitro associated with delayed-type hypersensitivity
3. The macrophage migration inhibitory factor MIF is a phenylpyruvate tautomerase
4. Characterization of the role of the amino-terminal proline in the enzymatic activity catalyzed by macrophage migration inhibitory factor
5. A macrophage migration inhibitory factor is expressed in the differentiating cells of eye lens
6. Identification of macrophage migration inhibitory factor in adipose tissue and its induction by tumor necrosis factor-α
7. Identification of macrophage migration inhibitory factor (MIF) in human skin and its immunohistochemical localization
8. Immunocytochemical localization of macrophage migration inhibitory factor in human hypophysis and pituitary adenomas
9. The macrophage is an important and previously unrecognized source of macrophage migration inhibitory factor
10. MIF rediscovered: Cytokine, pituitary hormone, and glucocorticoid-induced regulator of the immune responce
11. Macrophage migration inhibitory factor (MIF): A glucocorticoid counter-regulator within the immune system
12. Macrophage migration inhibitory factor in the human prostate: Identification and immunocytochemical localization
13. Enhanced expression of macrophage migration inhibitory factor in prostatic adenocarcinoma metastases
14. Expression of macrophage migration inhibitory factor in the human prostate
15. Infiltration of mononuclear inflammatory cells into primary colorectal carcinomas: An immunohistological analysis
16. Protein expression profiles in human breast ductal carcinoma and histologically normal tissue
17. Involvement of macrophage migration inhibitory factor (MIF) in the mechanism of tumor cell growth
18. Novel pathophysiological aspects of macrophage migration inhibitory factor
19. Classification of prostatic carcinomas
20. Inference network-based analyses of the histopathological effects of androgen deprivation on prostate cancer
21. Charge heterogeneity of macrophage migration inhibitory factor (MIF) in human liver and breast tissue
22. A proinflammatory cytokine inhibits p53 tumor suppressor activity
23. Experience with flutamide in patients with advanced prostatic cancer without prior endocrine therapy
24. A controlled trial of leuprolide with and without flutamide in prostatic carcinoma
25. Pathologic changes associated with androgen deprivation therapy for prostate cancer
26. Downstaging of localized prostate cancer by neoadjuvant therapy with flutamide and lupron: The first controlled and randomized trial
27. Clinical and pathobiological effects of neoadjuvant total androgen ablation therapy on clinically localized prostatic adenocarcinoma
28. Effects of combination endocrine treatment on normal prostate, prostatic intraepithelial neoplasia, and prostatic adenocarcinoma
29. Androgen deprivation therapy prior to radical prostatectomy for T2b and T3 prostate cancer
30. Pathological changes in prostate lesions after androgen manipulation
31. Effect of combination endocrine therapy (LHRH agonist and flutamide) on normal prostate and prostatic adenocarcinoma
32. Histologic changes in prostate carcinomas treated with leuprolide (luteinizing hormone-releasing hormone effect): Distinction from poor tumor differentiation
33. Androgen-deprived prostate adenocarcinoma: Evaluation of treatment-related changes versus no distinctive treatment effect with a Bayesian Belief Network
34. Effect of neoadjuvant endocrine therapy (combined androgen blockade) on normal prostate and prostatic carcinoma: A randomized study
35. Prostate-specific antigen, a serine protease, facilitates human prostate cancer cell invasion
36. Secretory products of macrophages
37. Monocyte chemotactic proteins from human tumor cells
38. Effects of mast cell-macrophage interactions on the production of collagenolytic enzymes by metastatic tumor cells and tumor-derived and stromal fibroblasts
39. Urokinase and macrophages in tumour angiogenesis
40. Association of macrophage infiltration with angiogenesis and prognosis in invasive breast carcinoma
41. Analysis of the expression of macrophage migration inhibitory factor (MIF) and the prognosis in lung adenocarcinomas